2022
31 August, 2022
FluoGuide appoints new CFO
Henrik Hang comes most recently from the role as CFO at Cyxone AB (publ). Henrik Hang has a degree in finance from University of Linné...
FluoGuide has now received approval from the Danish Ethical Committee and the trial can start in Denmark. FluoGuide announced in April...
In H1 2022, FluoGuide reached a major milestone in the clinical development showing that FG001 is very well tolerated and FG001 illuminates...
24 August, 2022
FluoGuide’s update on FG001’s clinical development
FluoGuide announced in April FG001’s highly promising results in aggressive brain cancer (high grade glioma) following its phase...
Following approval from the Danish Medicines Agency, FluoGuide will initiate the phase II trial in collaboration with Department of...
22 August, 2022
Publication of clinical data confirming uPAR as an attractive target for guiding surgery in head and neck cancer
The article documents the relevance of uPAR as target for guiding surgery of head and neck cancers relative to other molecular targets...
. *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total number...
As a follow-up on the presentation done by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen in Bergen, FluoGuide...
The board of directors hereby convenes an annual general meeting of FluoGuide to be held on: Wednesday 18 May 2022 at 11:00 (CET) at...